Sana Biotechnology (SANA) Stock Overview
A biotechnology company, focuses on utilizing engineered cells as medicines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SANA Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Sana Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.59 |
| 52 Week High | US$7.30 |
| 52 Week Low | US$1.26 |
| Beta | 1.91 |
| 1 Month Change | 67.37% |
| 3 Month Change | 28.21% |
| 1 Year Change | 47.88% |
| 3 Year Change | -3.95% |
| 5 Year Change | n/a |
| Change since IPO | -84.07% |
Recent News & Updates
Recent updates
Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight
Oct 16Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421
Mar 25Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Jan 08Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
Dec 04Sana Biotechnology: The Story Becomes Murkier
Nov 19We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully
Nov 01
Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline
Jul 14We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Jul 12Sana Biotechnology: Now In Overbought Territory
Mar 17Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
Jan 11Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
Dec 30Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 14Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
May 26We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Shareholder Returns
| SANA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.1% | 0.2% | 2.1% |
| 1Y | 47.9% | 3.9% | 18.7% |
Return vs Industry: SANA exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: SANA exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| SANA volatility | |
|---|---|
| SANA Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SANA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SANA's weekly volatility has decreased from 28% to 17% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 194 | Steve Harr | www.sana.com |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases.
Sana Biotechnology, Inc. Fundamentals Summary
| SANA fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | -US$252.18m |
| Revenue (TTM) | n/a |
Is SANA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$252.18m |
| Earnings | -US$252.18m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SANA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/28 18:36 |
| End of Day Share Price | 2025/10/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sana Biotechnology, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Samantha Lynn Semenkow | Citigroup Inc |
| Samantha Lynn Semenkow | Citigroup Inc |